Literature DB >> 788890

Factors influencing survival of children with nonmetastatic neuroblastoma.

A E Evans, V Albo, G J D'Angio, J Z Finklestein, S Leiken, T Santulli, J Weiner, G D Hammond.   

Abstract

A randomized study was designed to determine the effect of intermittent oral cyclophosphamide on the rate of metastases in children with localized and regional neuroblastoma. Secondary objectives of the study were to determine the value of the proposed staging system, to measure the influence of the peripheral lymphocyte count on prognosis, and to study the effect of the primary tumor site and regional node involvement. Since there was no difference in survival in the two groups of patients, whether or not they received chemotherapy, all 113 children were treated as a single group for the analysis of the secondary objectives. The proposed staging served as a good indicator of prognosis with a significant difference in survival seen between each of three stages. It was not possible to detect a significant influence by the three other prognostic variables studied, peripheral lymphocytes, primary site and regional node involvement. Small numbers in the various subgroups studied may account for the failure of differences to achieve statistical significance.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788890     DOI: 10.1002/1097-0142(197608)38:2<661::aid-cncr2820380206>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Management of Wilms' tumor and neuroblastoma.

Authors:  P Mehta; T Vats
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

2.  Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.

Authors:  Anneleen Decock; Maté Ongenaert; Bram De Wilde; Bénédicte Brichard; Rosa Noguera; Frank Speleman; Jo Vandesompele
Journal:  Epigenetics       Date:  2016-10-02       Impact factor: 4.528

3.  N-myc amplification in neuroblastomas: histopathological, DNA ploidy, and clinical variables.

Authors:  B R Oppedal; O Oien; T Jahnsen; P Brandtzaeg
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

4.  Prognostic value of different staging systems in neuroblastomas and completeness of tumour excision.

Authors:  N L Carlsen; I J Christensen; H Schroeder; P V Bro; U Hesselbjerg; K B Jensen; O H Nielsen
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

5.  Neuroepithelioma (neuroblastoma) arising in an adult. A case report.

Authors:  J Verwey; R Slater; W Kamphorst; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors.

Authors:  D R Keim; N Hailat; R Kuick; C P Reynolds; G M Brodeur; R C Seeger; S M Hanash
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

7.  Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement.

Authors:  J Ninane; J Pritchard; P H Morris Jones; J R Mann; J S Malpas
Journal:  Arch Dis Child       Date:  1982-06       Impact factor: 3.791

8.  The impact of chemotherapy and radiation therapy on secondary operations for neuroblastoma.

Authors:  E I Smith; H F Krous; W P Tunell; D C Hitch
Journal:  Ann Surg       Date:  1980-05       Impact factor: 12.969

9.  Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma.

Authors:  J C Hoehner; C Gestblom; L Olsen; S Påhlman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Authors:  H Rubie; J Michon; D Plantaz; M C Peyroulet; C Coze; D Frappaz; P Chastagner; M C Baranzelli; F Méchinaud; P Boutard; P Lutz; Y Perel; G Leverger; L de Lumley; F Millot; J L Stéphan; G Margueritte; O Hartmann
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.